Androgen receptor blockade may have clinical utility in treating cancers other than prostate cancer. Several mouse studies have found that antiandrogen drugs boost the efficacy of immune checkpoint inhibitors and help combat resistance to targeted agents for a variety of tumor types. Clinical trials are underway to assess AR inhibition as an adjunct to multiple forms of cancer therapy.

You do not currently have access to this content.